Close

EPA Should Deny Petition to Waive Renewable Fuel Standard Obligations

Feb 16 2012
The RFS and EPA’s consistent implementation are the fundamental policy drivers for the continued development of advanced biofuels and cellulosic biofuels. It provides industry and investors with the confidence of knowing that if they can produce advanced and cellulosic biofuels, the RFS will ensure market access for those types of fuels. 

2012 Special 301 Report: Biotech's International IP Issues

Feb 14 2012
BIO has identified the following countries of interest and recommends the following for our 2011 Special 301 submission.

Alzheimer’s Disease: BIO's Comments on the Draft Framework for the National Plan to Address Alzheimer’s Disease

Feb 7 2012

...

PDUFA V: Testimony to House Committee on Energy and Commerce, Subcommittee on Health

Jan 31 2012

...

Essential Health Benefit: BIO's Comments on the HHS Pre-rule Bulletin

Jan 30 2012

...

USPTO Satellite Offices: Biotechnology Hubs Ideal Place

Jan 29 2012

...

BIO Comments on CMS Proposed Methodology for 2013 Star Ratings for Medicare Advantage and Prescription Drug Plans

Jan 20 2012
BIO supports the development and use of appropriate, evidence-based quality measures throughout the healthcare system. Quality measures for adult immunizations help ensure that healthcare providers routinely discuss and offer vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) to their patients, resulting in higher vaccine uptake among adults, better health outcomes, improved population health and cost savings for public and private insurance plans.

Coverage with Evidence Development: BIO's Comments on the Centers for Medicare and Medicaid Services’ (CMS) public solicitation for comments on Coverage with Evidence Development (CED)

Jan 19 2012

...

Orphan Drugs: BIO Submits Comments on Orphan Drug Regulations

Jan 16 2012

...

Bar Code Technologies: BIO Comments on FDA's Bar Code Technologies for Drugs and Biological Products; Retrospective Review under Executive Order 13563

Jan 8 2012

...